Compare GNT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | SLGL |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 117.8M |
| IPO Year | N/A | 2018 |
| Metric | GNT | SLGL |
|---|---|---|
| Price | $8.57 | $51.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 40.9K | 23.6K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.36 | ★ N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $4.59 | $4.02 |
| 52 Week High | $5.40 | $75.00 |
| Indicator | GNT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 81.37 | 53.07 |
| Support Level | $7.72 | $60.20 |
| Resistance Level | $8.14 | $75.00 |
| Average True Range (ATR) | 0.16 | 7.13 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 98.08 | 40.76 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.